Cargando…

Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden

Oral corticosteroids (OCS) are often prescribed to patients with asthma that remains uncontrolled with maintenance therapy. We performed a real-world analysis to describe the geographic distributions of patients with asthma and OCS dispensed in Nordic countries. This observational, retrospective stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehtimäki, Lauri, Arvidsson, Monica, Erdemli, Bora, Nan, Cassandra, Nguyen, Tra-My, Samant, Aditya, Telg, Gunilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067971/
https://www.ncbi.nlm.nih.gov/pubmed/35529252
http://dx.doi.org/10.1080/20018525.2022.2066815
_version_ 1784700128655835136
author Lehtimäki, Lauri
Arvidsson, Monica
Erdemli, Bora
Nan, Cassandra
Nguyen, Tra-My
Samant, Aditya
Telg, Gunilla
author_facet Lehtimäki, Lauri
Arvidsson, Monica
Erdemli, Bora
Nan, Cassandra
Nguyen, Tra-My
Samant, Aditya
Telg, Gunilla
author_sort Lehtimäki, Lauri
collection PubMed
description Oral corticosteroids (OCS) are often prescribed to patients with asthma that remains uncontrolled with maintenance therapy. We performed a real-world analysis to describe the geographic distributions of patients with asthma and OCS dispensed in Nordic countries. This observational, retrospective study examined patient-level data from nationally prescribed drug registries from January to December 2018 for individuals aged ≥12 years in Denmark, Finland, and Sweden. Using an algorithm based on asthma treatment combinations defined by the Global Initiative for Asthma (GINA), we identified patients with asthma, those on GINA Step 4–5 treatments, and those being dispensed ≥2 courses of OCS and determined volumes of OCS dispensed to these patients over the 1-year analysis period. Data were plotted geographically within each country using colour-coded heat maps. The overall asthma prevalence rates were 7.4% in Denmark, 11.6% in Finland, and 8.1% in Sweden. In Denmark, Finland, and Sweden, respectively, the frequencies of patients on GINA Step 4–5 treatments were 19%, 15%, and 16%; among whom 10%, 23%, and 5% received ≥2 courses of OCS. The rates of patients on GINA Step 4–5 treatments who were dispensed OCS in each country were 23%, 30%, and 46%, of which 22%, 17%, and 10% were dispensed doses averaging ≥5 mg/day over the year. Heat maps revealed considerable heterogeneity in geographic densities of patients with asthma and OCS claims within each country. Taken together, these results demonstrate regional variations in estimated asthma severity, control, and OCS dispensed within and between countries. Patterns of medication use suggest that a high proportion of patients in Denmark, Finland, and Sweden are on GINA Step 4–5 treatments, many of whom are dispensed OCS; this poses a considerable corticosteroid burden to these patients. Geographic differences in medication use within and between Nordic countries may reflect variations in population characteristics and/or treatment approaches.
format Online
Article
Text
id pubmed-9067971
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-90679712022-05-05 Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden Lehtimäki, Lauri Arvidsson, Monica Erdemli, Bora Nan, Cassandra Nguyen, Tra-My Samant, Aditya Telg, Gunilla Eur Clin Respir J Research Article Oral corticosteroids (OCS) are often prescribed to patients with asthma that remains uncontrolled with maintenance therapy. We performed a real-world analysis to describe the geographic distributions of patients with asthma and OCS dispensed in Nordic countries. This observational, retrospective study examined patient-level data from nationally prescribed drug registries from January to December 2018 for individuals aged ≥12 years in Denmark, Finland, and Sweden. Using an algorithm based on asthma treatment combinations defined by the Global Initiative for Asthma (GINA), we identified patients with asthma, those on GINA Step 4–5 treatments, and those being dispensed ≥2 courses of OCS and determined volumes of OCS dispensed to these patients over the 1-year analysis period. Data were plotted geographically within each country using colour-coded heat maps. The overall asthma prevalence rates were 7.4% in Denmark, 11.6% in Finland, and 8.1% in Sweden. In Denmark, Finland, and Sweden, respectively, the frequencies of patients on GINA Step 4–5 treatments were 19%, 15%, and 16%; among whom 10%, 23%, and 5% received ≥2 courses of OCS. The rates of patients on GINA Step 4–5 treatments who were dispensed OCS in each country were 23%, 30%, and 46%, of which 22%, 17%, and 10% were dispensed doses averaging ≥5 mg/day over the year. Heat maps revealed considerable heterogeneity in geographic densities of patients with asthma and OCS claims within each country. Taken together, these results demonstrate regional variations in estimated asthma severity, control, and OCS dispensed within and between countries. Patterns of medication use suggest that a high proportion of patients in Denmark, Finland, and Sweden are on GINA Step 4–5 treatments, many of whom are dispensed OCS; this poses a considerable corticosteroid burden to these patients. Geographic differences in medication use within and between Nordic countries may reflect variations in population characteristics and/or treatment approaches. Taylor & Francis 2022-05-02 /pmc/articles/PMC9067971/ /pubmed/35529252 http://dx.doi.org/10.1080/20018525.2022.2066815 Text en © 2022 AstraZeneca. Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lehtimäki, Lauri
Arvidsson, Monica
Erdemli, Bora
Nan, Cassandra
Nguyen, Tra-My
Samant, Aditya
Telg, Gunilla
Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden
title Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden
title_full Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden
title_fullStr Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden
title_full_unstemmed Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden
title_short Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden
title_sort regional variation in intensity of inhaled asthma medication and oral corticosteroid use in denmark, finland, and sweden
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067971/
https://www.ncbi.nlm.nih.gov/pubmed/35529252
http://dx.doi.org/10.1080/20018525.2022.2066815
work_keys_str_mv AT lehtimakilauri regionalvariationinintensityofinhaledasthmamedicationandoralcorticosteroiduseindenmarkfinlandandsweden
AT arvidssonmonica regionalvariationinintensityofinhaledasthmamedicationandoralcorticosteroiduseindenmarkfinlandandsweden
AT erdemlibora regionalvariationinintensityofinhaledasthmamedicationandoralcorticosteroiduseindenmarkfinlandandsweden
AT nancassandra regionalvariationinintensityofinhaledasthmamedicationandoralcorticosteroiduseindenmarkfinlandandsweden
AT nguyentramy regionalvariationinintensityofinhaledasthmamedicationandoralcorticosteroiduseindenmarkfinlandandsweden
AT samantaditya regionalvariationinintensityofinhaledasthmamedicationandoralcorticosteroiduseindenmarkfinlandandsweden
AT telggunilla regionalvariationinintensityofinhaledasthmamedicationandoralcorticosteroiduseindenmarkfinlandandsweden